Single Ascending Doses of BIIB063 in Healthy Volunteers
Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
West Yorkshire
-
Leeds, West Yorkshire, Det Forenede Kongerige, LD2 9LH
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
- Must have a body mass index between 18 and 30 kg/m2, inclusive.
- Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.
Key Exclusion Criteria:
- History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
- History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
- Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
- History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
- History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
- Personal history of thromboembolic events
- Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
- Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
- Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
- Blood donation (1 unit or more) within 3 months prior to randomization.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Enkelt dosis
|
|
Eksperimentel: IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Enkelt dosis
|
|
Eksperimentel: IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Enkelt dosis
|
|
Eksperimentel: IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Enkelt dosis
|
|
Eksperimentel: IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Enkelt dosis
|
|
Eksperimentel: IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Enkelt dosis
|
|
Eksperimentel: IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Enkelt dosis
|
|
Eksperimentel: SC Dose
Single SC dose or matching placebo
|
Single ascending IV dose
Enkelt dosis
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant laboratory assessment abnormalities
Tidsramme: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant Vital sign abnormalities
Tidsramme: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Tidsramme: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant physical examination abnormalities
Tidsramme: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for tetanus
Tidsramme: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for diphtheria
Tidsramme: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for pneumococcus
Tidsramme: Up to week 12
|
Up to week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
Tidsramme: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
Tidsramme: Up to week 12
|
Up to week 12
|
|
Number of participants with positive serum anti-BIIB063 antibodies
Tidsramme: Up to week 12
|
Up to week 12
|
|
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
Tidsramme: Up to 12 weeks
|
Up to 12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 234HV101
- 2015-001283-18 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .